Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
The non-label dialysis regimens are separate GlobalRPh reference material, not manufacturer instructions. No renal-adjusted meningitis regimen is inferred.
Check source scope before reading a dose
UCSF - meropenem: indication-specific renal doses
Product / population
Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.
Renal method
CrCl in mL/min where specified; no equation inferred.
Source revision
Revision date not stated in the reviewed page.
Retrieved
2026-09-05
Local review status
Locally included source-specific summary. Regimen differences are not automatically resolved.
UCSF Infectious Diseases Management Program · Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.
Renal method: CrCl in mL/min where specified; no equation inferred. Source date: Revision date not stated in the reviewed page. Retrieved: 2026-09-05
Locally included source-specific summary. Regimen differences are not automatically resolved.
Dosing / renal protocol and limits
IV short-infusion regimens for renal bands >50 / 26-50 / 10-25 / <10 mL/min:
Standard: 1 g every 8 hours / 1 g every 12 hours / 500 mg every 12 hours / 500 mg daily.
Meningitis or cystic fibrosis: 2 g every 8 hours / 2 g every 12 hours / 1 g every 12 hours / 1 g daily.
IHD: standard 500 mg initially, then every evening; meningitis/cystic fibrosis 1 g initially, then every evening.
CVVHD: standard 1 g every 8 hours; meningitis/cystic fibrosis 2 g every 12 hours. Discuss flow exceeding 2 L/hour with ID pharmacy.
Selected extended infusion uses a 1 g loading dose over 30 minutes, with maintenance beginning 4 hours later. At renal function >50 / 26-50, standard maintenance is 1 g over 3 hours every 8 / 12 hours; meningitis/cystic fibrosis maintenance is 2 g at those intervals. Below 26, use short infusion. Meningitis extended-infusion evidence is limited.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.